Literature DB >> 17257800

Improved survival after introduction of an emergency endovascular therapy protocol for ruptured abdominal aortic aneurysms.

Randy Moore1, Mark Nutley, Claudio S Cina, Mona Motamedi, Peter Faris, Wesam Abuznadah.   

Abstract

BACKGROUND: The study was conducted to demonstrate improved survival (30-day mortality) after the introduction of an emergency endovascular therapy protocol for ruptured abdominal aortic aneurysms (rAAA). Numerous authors have successfully demonstrated reduced mortality in patients with rAAA using endovascular techniques. Comparison of endovascular aneurysm repair (EVAR) with open repair for rAAA may be misleading, however, because EVAR cannot be performed on all patients, and selection bias may explain the superior performance of any given surgical or endovascular strategy. We developed a model to predict mortality in patients before the introduction of EVAR (preprotocol population), applied this model to predict 30-day mortality among prospective patients (postprotocol population), and compared observed vs expected results.
METHODS: We assessed 126 patients with rAAA. Primary outcome was 30-day mortality. Potential confounding variables were age, sex, presurgical lowest recorded systolic blood pressure (SBP), and glomerular filtration rate (GFR). A logistic regression model incorporating significant confounders was used to evaluate changes in 30-day mortality for all patients with rAAA after introduction of the EVAR protocol. Separate logistic regressions were done to compare 30-day mortality for preprotocol vs patients receiving EVAR and preprotocol vs patients receiving postprotocol open repair. Cumulative sum (CUSUM) analysis was used to assess shifts in the performance of the rAAA program over time.
RESULTS: Significant confounders were SBP, absence of SBP, and GFR. Logistic regression found evidence of lower mortality after the protocol was introduced, 17.9% vs 30.0% (odds ratio [OR], 0.385; 95% confidence interval [CI], 0.141 to 0.981; P = .046). Comparison of all open repairs (preprotocol and postprotocol) and EVAR demonstrated decreased risk for EVAR of 5.0% vs 28.3% (OR, 0.109; 95% CI, 0.013 to 0.906; P = .0084). Unstable patients (SBP <or=80) showed a trend towards improved survival with EVAR relative to open repair (14.3% vs 56.0%, P = .061). Comparison of preprotocol surgery with open repair after the introduction of the protocol found no evidence of a difference between mortality rates for the open procedures-30.0% (preprotocol) vs 25.0% (postprotocol; OR, 0.688; 95% CI, 0.335 to 1.415, P = .3031)-demonstrating that the improved performance observed with CUSUM analysis was related to the introduction of the EVAR protocol.
CONCLUSION: Our predictive model using "weighted" CUSUM analysis (a measure of performance over time) demonstrated that a predefined strategy of management of rAAA that includes EVAR is associated with improved (P < .05) mortality. Unstable patients with rAAA may be particularly benefited by EVAR and should not be excluded from repair. Appropriate patients with rAAA who are undergoing treatment in experienced vascular centers should be offered EVAR as the treatment of choice.

Entities:  

Mesh:

Year:  2007        PMID: 17257800     DOI: 10.1016/j.jvs.2006.11.047

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  18 in total

1.  Comparison of open and endovascular repair of ruptured abdominal aortic aneurysms from the ACS-NSQIP 2005-07.

Authors:  Kristina A Giles; Frank B Pomposelli; Allen D Hamdan; Mark C Wyers; Marc L Schermerhorn
Journal:  J Endovasc Ther       Date:  2009-06       Impact factor: 3.487

2.  Endovascular repair of thoracic and abdominal aortic ruptures: a single-center experience.

Authors:  Filiz İslim; Aysun Erbahçeci Salık; Koray Güven; Vedat Bakuy; Zafer Çukurova
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

3.  Significant regional variation exists in morbidity and mortality after repair of abdominal aortic aneurysm.

Authors:  Sara L Zettervall; Peter A Soden; Dominique B Buck; Jack L Cronenwett; Phillip P Goodney; Mohammad H Eslami; Jason T Lee; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-11-23       Impact factor: 4.268

4.  Management of symptomatic abdominal aortic aneurysms following emergency computed tomography.

Authors:  Masahiro Matsushita; Teruo Ikezawa; Masayuki Sugimoto; Akihito Idetsu
Journal:  Surg Today       Date:  2013-02-16       Impact factor: 2.549

5.  Comparison of survival rates for abdominal aortic aneurysm treatment methods.

Authors:  Irene Hinterseher; Herold Kuffner; Rainer Koch; Gabor Gäbel; Hans D Saeger; Diane Smelser
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

6.  Endovascular treatment of aortic aneurysms: state of the art.

Authors:  Jonathan L Eliason; Gilbert R Upchurch
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

7.  Regional variation exists in patient selection and treatment of abdominal aortic aneurysms.

Authors:  Sara L Zettervall; Dominique B Buck; Peter A Soden; Jack L Cronenwett; Phillip P Goodney; Mohammad H Eslami; Jason T Lee; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-04-08       Impact factor: 4.268

8.  Open surgery (OS) versus endovascular aneurysm repair (EVAR) for hemodynamically stable and unstable ruptured abdominal aortic aneurysm (rAAA).

Authors:  Simeng Zhang; Jiaxuan Feng; Haiyan Li; Yongxue Zhang; Qingsheng Lu; Zaiping Jing
Journal:  Heart Vessels       Date:  2015-09-03       Impact factor: 2.037

9.  Decrease in total aneurysm-related deaths in the era of endovascular aneurysm repair.

Authors:  Kristina A Giles; Frank Pomposelli; Allen Hamdan; Mark Wyers; Ami Jhaveri; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2009-01-09       Impact factor: 4.268

Review 10.  Endovascular Treatment of Various Aortic Pathologies: Review of the Latest Data and Technologies.

Authors:  Koji Maeda; Takao Ohki; Yuji Kanaoka
Journal:  Int J Angiol       Date:  2018-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.